US Personalized Cancer Genome Sequencing Market Outlook 2018
Format : Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Mar, 2014| No. of Pages : 65
1. Analyst View
2. Research Methodology
3. Genome Sequencing: An Introduction
4. Cancer Statistics by Demographics
4.1 Prevalence, Incidences, and Mortality (2010-2018)
4.2 Leading States by Incidence
4.3 Leading Cancers by Incidence
4.3.1 Male Cancer Incidences
4.3.2 Female Cancer Incidences
4.3.3 Age-Group
5. US Personalized Cancer WGS Potential Market to 2018
6. US Personalized Cancer WGS: Current and Future Market Analysis
7. Regulatory Insights
7.1 Clinical Laboratory Improvement Amendments (CLIA) Accreditation
7.2 CAP Accreditation
8. Market Constraints
9. Competitive Assessment
9.1 Illumina
9.1.1 Business Overview
9.1.2 Key Information
9.1.3 Strengths and Weaknesses
9.2 Complete Genomics
9.2.1 Business Overview
9.2.2 Key Information
9.2.3 Strengths and Weaknesses
9.3 Beckman Coulter Genomics
9.3.1 Business Overview
9.3.2 Key Information
9.3.3 Strengths and Weaknesses
9.4 Expression Analysis
9.4.1 Business Overview
9.4.2 Key Information
9.4.3 Strengths and Weaknesses
9.5 EdgeBio
9.5.1 Business Overview
9.5.2 Key Information
9.5.3 Strengths and Weaknesses
9.6 Foundation Medicine
9.6.1 Business Overview
9.6.2 Key Information
9.6.3 Strengths and Weaknesses
9.7 SeqWright
9.7.1 Business Overview
9.7.2 Key Information
9.7.3 Strengths and Weaknesses
9.8 Ambry Genetics
9.8.1 Business Overview
9.8.2 Key Information
9.8.3 Strengths and Weaknesses
9.9 BGI Americas Corporation
9.9.1 Business Overview
9.9.2 Key Information
9.9.3 Strengths and Weaknesses
9.10 Cofactor Genomics
9.10.1 Business Overview
9.10.2 Key Information
9.10.3 Strengths and Weaknesses